Octreotide attenuates intestinal ischemia/reperfusion mischief in rats through modulation of Nrf2/PRX2/ASK1/JNK

Nermein F El Sayed1, Diaa Ragab2, Walied Abdo3

  • 1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ahram Canadian University, Giza, Egypt.

Insights

Octreotide protects against intestinal ischemia/reperfusion (IIR) injury by activating antioxidant, anti-apoptotic, and anti-inflammatory pathways. It triggers autophagy and modulates the Nrf2/PRX2/ASK1/JNK signaling pathway, improving intestinal tissue health.

Area of Science:

  • Gastroenterology
  • Cell Biology
  • Molecular Medicine

Background:

  • Intestinal ischemia/reperfusion (IIR) injury is a significant clinical problem with high mortality.
  • Octreotide (OCT) shows promise in treating organ insults, but its mechanism in IIR is unclear.

Purpose of the Study:

  • To investigate the protective effects of octreotide in a rat model of intestinal ischemia/reperfusion (IIR).
  • To elucidate the underlying molecular mechanisms of octreotide's action in IIR.

Main Methods:

  • Rats were subjected to sham operation, IIR, or IIR with OCT treatment.
  • Histopathological analysis, immunohistochemistry, real-time PCR, western blot, ELISA, and comet assay were employed.
  • Key markers assessed included NF-κB, Bcl2, caspase-3, IL-17, LC3B, beclin-1, TNF-α, Nrf2, and JNK signaling pathway components.

Main Results:

  • Octreotide upregulated antioxidant capacity (TAC, SOD) and anti-apoptotic markers (Bcl2), while downregulating pro-apoptotic markers (Bax, caspase-3).
  • OCT reduced inflammatory markers (TNF-α, NF-κB, IL-17) and induced autophagy (beclin-1, LC3B).
  • Molecularly, OCT increased p-Nrf2 and PRX2, and decreased ASK1 and p-JNK, indicating modulation of the Nrf2/PRX2/ASK1/JNK pathway.

Conclusions:

  • Octreotide effectively ameliorates IIR-induced intestinal injury.
  • Its protective effects are mediated through a combination of antioxidant, anti-apoptotic, anti-inflammatory, and autophagic mechanisms.
  • Modulation of the Nrf2/PRX2/ASK1/JNK signaling pathway is central to octreotide's therapeutic action in IIR.